Versigent (NYSE:VGNT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $46.6667.
Several equities research analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on Versigent in a report on Tuesday, March 31st. They set a “sector perform” rating and a $28.00 price target for the company. Fox Advisors raised Versigent to a “strong-buy” rating in a report on Tuesday, April 7th. Wells Fargo & Company raised their price target on Versigent from $35.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. BNP Paribas Exane assumed coverage on Versigent in a report on Tuesday, April 28th. They set an “outperform” rating and a $41.00 price target for the company. Finally, Wall Street Zen raised Versigent to a “hold” rating in a report on Saturday, April 18th.
View Our Latest Stock Analysis on Versigent
Versigent Price Performance
Versigent (NYSE:VGNT – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $999.00 earnings per share (EPS) for the quarter.
Further Reading
- Five stocks we like better than Versigent
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
